MDRTB and additional drug resistances: years 2008 and 2009 (complete drug profiles)
| 2008+2009 | ||
| N | % | |
| Total MDRTB strains with complete DST profile | 107 | 100% |
| Group 1 | ||
| MDRTB (R+H) | 51 | 48% |
| MDRTB (R+H)+resistance to any reserve drug* | 17 | 33% |
| MDRTB (R+H)+sensitivity to all reserve drugs* | 34 | 67% |
| Group 2 | ||
| MDRTB (R+H)+/or E+/or Z | 56 | 52% |
| MDRTB (R+H)+/or E+/or Z+resistance to reserve any drugs* | 34 | 61% |
| MDRTB (R+H)+sensitivity to all reserve drugs* | 22 | 39% |
| Resistance to first-line drugs | ||
| Ethambutol | 48 | 45% |
| Pyrazinamide | 30 | 28% |
| Resistance to reserve drugs | ||
| Injectables† | 6 | 6% |
| Quinolones‡ | 21 | 20% |
| Prothionamide | 41 | 38% |
| Streptomycin | 68 | 64% |
| XDR | 3 | 3% |
In multidrug-resistant tuberculosis (MDRTB) isolates the rate of resistance to any reserve drug was significantly greater when accompanied by resistance to another first line drug (group 2 vs group 1) (Fisher's exact test p=0.0065).
↵* Reserve drugs: amikacin, capreomycin, kanamycin, moxifloxacin, ofloxacin and prothionamide (streptomycin is not included).
↵† Any of amikacin, capreomycin and kanamycin.
↵‡ Ofloxacin and/or moxifloxacin.
DST, drug sensitivity test; E, ethambutol; H, isoniazid; R, rifampicin; XDR, extensively drug resistant; Z, pyrazinamide.